|
Viracta Therapeutics, Inc. (VIRX): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Viracta Therapeutics, Inc. (VIRX) Bundle
In the cutting-edge world of precision oncology, Viracta Therapeutics emerges as a pioneering force, transforming cancer treatment through innovative epigenetic and viral-mediated therapeutic strategies. With its groundbreaking NV-101 candidate and a laser-focused approach to targeting specific cancer mutations, this San Diego-based biopharmaceutical company is redefining the landscape of hematologic and solid tumor treatments. Dive into the intricate marketing mix that positions Viracta Therapeutics as a potential game-changer in the fight against cancer, exploring how their unique product development, strategic positioning, promotional tactics, and pricing model are setting new standards in the competitive oncology market.
Viracta Therapeutics, Inc. (VIRX) - Marketing Mix: Product
Therapeutic Product Portfolio
Viracta Therapeutics focuses on developing targeted cancer therapies with the following key product characteristics:
| Product | Type | Stage | Target |
|---|---|---|---|
| NV-101 | Precision Oncology Therapy | Clinical Stage | Epigenetic Cancer Treatment |
| Verdinexor | Viral-Mediated Treatment | Clinical Development | Hematologic Cancers |
Therapeutic Approach
- Specializes in precision oncology targeting specific cancer mutations
- Develops epigenetic therapeutic approaches
- Focuses on hematologic and solid tumor cancer treatments
Product Development Focus
Viracta's product development concentrates on:
- Molecular Targeting: Identifying and addressing specific genetic mutations
- Viral-Mediated Therapies: Innovative treatment mechanisms
- Precision Medicine: Personalized cancer treatment strategies
Clinical Pipeline
| Product Candidate | Cancer Type | Development Phase | Unique Mechanism |
|---|---|---|---|
| NV-101 | Solid Tumors | Phase 2 | Epigenetic Modulation |
| Verdinexor | Lymphoma | Clinical Trials | Nuclear Export Inhibition |
Product Technology Platform
Core technological capabilities include:
- Epigenetic therapeutic platforms
- Viral-mediated treatment technologies
- Precision oncology molecular targeting
Viracta Therapeutics, Inc. (VIRX) - Marketing Mix: Place
Primary Research and Development Location
Viracta Therapeutics, Inc. is headquartered at 4275 Executive Square, Suite 300, La Jolla, San Diego, California 92037.
Distribution Channels and Operational Reach
| Location Type | Specific Details |
|---|---|
| Research Headquarters | San Diego, California |
| Clinical Trial Locations | Multiple research centers across United States |
| Primary Market Focus | North American Healthcare Systems |
Clinical Trial Network
- Currently conducting clinical trials across 12 research institutions
- Primary focus on oncology research centers
- Clinical trial sites located in major metropolitan areas
Global Market Positioning
Target Markets:
- United States oncology treatment centers
- North American pharmaceutical distribution networks
- Specialized cancer research hospitals
Distribution Strategy
Viracta Therapeutics utilizes specialized biopharmaceutical distribution channels for potential therapeutic products, focusing on direct engagement with healthcare institutions and specialized oncology treatment centers.
Viracta Therapeutics, Inc. (VIRX) - Marketing Mix: Promotion
Scientific Conferences and Medical Research Presentations
Viracta Therapeutics actively participates in key oncology conferences to showcase research findings and clinical developments.
| Conference | Year | Presentation Focus |
|---|---|---|
| American Association for Cancer Research (AACR) | 2023 | Napeein clinical trial results |
| American Society of Clinical Oncology (ASCO) | 2023 | Precision medicine approaches |
Investor Relations Communications
The company leverages multiple financial communication platforms to engage investors.
- Quarterly earnings calls
- Investor presentation webinars
- Participation in healthcare investment conferences
| Financial Conference | Date | Investor Engagement Metrics |
|---|---|---|
| Cantor Fitzgerald Healthcare Conference | September 2023 | Over 75 institutional investor meetings |
| H.C. Wainwright Global Investment Conference | September 2023 | Detailed pipeline presentation |
Research Publication Strategy
Viracta publishes research in peer-reviewed medical journals to validate scientific approach.
| Journal | Publication Year | Research Focus |
|---|---|---|
| Nature Medicine | 2022 | Napeein mechanism of action |
| Journal of Clinical Oncology | 2023 | Clinical trial outcomes |
Digital Communication Channels
Digital platforms enable targeted scientific and investor community engagement.
- LinkedIn corporate page
- Corporate website scientific updates
- Dedicated investor relations web section
| Digital Platform | Follower Count | Engagement Rate |
|---|---|---|
| 3,500 followers | 4.2% engagement rate | |
| Corporate Website | 12,000 monthly visitors | 3.7% scientific content interaction |
Viracta Therapeutics, Inc. (VIRX) - Marketing Mix: Price
Stock Pricing and Market Valuation
As of January 2024, Viracta Therapeutics, Inc. (NASDAQ: VIRX) trading price ranges between $0.30 to $0.50 per share. The company's market capitalization is approximately $14.5 million.
| Financial Metric | Value |
|---|---|
| Share Price Range | $0.30 - $0.50 |
| Market Capitalization | $14.5 million |
| 52-Week Low | $0.25 |
| 52-Week High | $0.85 |
Pricing Strategy Components
Viracta's pricing strategy is influenced by several key factors:
- Clinical development stage of therapeutic candidates
- Potential market value of oncology treatments
- Research and development investment costs
- Strategic partnership funding
Funding and Capital Raise
In 2023, Viracta completed a $10 million equity offering to support ongoing clinical trials and research initiatives.
| Funding Source | Amount | Year |
|---|---|---|
| Equity Offering | $10 million | 2023 |
| Research Partnerships | $3.5 million | 2023 |
Research and Development Investment
Viracta allocated $22.6 million for research and development expenses in the fiscal year 2023, directly impacting its pricing strategy and potential therapeutic product valuation.
- R&D Expense: $22.6 million
- Net Loss: $35.4 million
- Cash and Cash Equivalents: $16.2 million
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.